Trial · NCT04089566
Results by group934
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 934
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part B Infantile-onset SMA: Change From Baseline in CHOP-INTEND Total Score for 50/28mg Nusinersen Versus CS3B Matched Sham Control Group | Part B: Infantile-Onset SMA: 50/28 mg Nusinersen | 42.9 | 95% Confidence Interval 38.7 to 47.2 | score on scale | |
| Part B Infantile-onset SMA: Change From Baseline in CHOP-INTEND Total Score for 50/28mg Nusinersen Versus CS3B Matched Sham Control Group | CS3B Matched Sham Control Group | 16.9 | 95% Confidence Interval 10.1 to 23.7 | score on scale | |
| Parts A and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs) | Part A: Nusinersen 28/28 mg | TEAEs | 4 | Participants | |
| Parts A and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs) | Part C: Nusinersen 50/28 mg | TEAEs | 37 | Participants | |
| Parts A and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs) | Part A: Nusinersen 28/28 mg | TESAEs | 1 | Participants | |
| Parts A and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs) | Part C: Nusinersen 50/28 mg | TESAEs | 6 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part A: Nusinersen 28/28 mg | Alkaline Phosphatase Shift to High | 1 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part C: Nusinersen 50/28 mg | Alkaline Phosphatase Shift to High | 2 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part A: Nusinersen 28/28 mg | Alanine Aminotransferase Shift to High | 0 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part C: Nusinersen 50/28 mg | Alanine Aminotransferase Shift to High | 6 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part A: Nusinersen 28/28 mg | Aspartate Aminotransferase Shift to High | 0 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part C: Nusinersen 50/28 mg | Aspartate Aminotransferase Shift to High | 8 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part A: Nusinersen 28/28 mg | Bicarbonate Shift to Low | 1 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part C: Nusinersen 50/28 mg | Bicarbonate Shift to Low | 6 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part A: Nusinersen 28/28 mg | Bicarbonate Shift to High | 0 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part C: Nusinersen 50/28 mg | Bicarbonate Shift to High | 2 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part A: Nusinersen 28/28 mg | Bilirubin Shift to High | 0 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part C: Nusinersen 50/28 mg | Bilirubin Shift to High | 1 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part A: Nusinersen 28/28 mg | Indirect Bilirubin Shift to Low | 4 | Participants | |
| Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters) | Part C: Nusinersen 50/28 mg | Indirect Bilirubin Shift to Low | 12 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04089566/results